High-dose intravenous methylprednisolone in juvenile non-infectious uveitis: A retrospective analysis

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Anja Schnabel - , Department of Paediatrics, Department of Paediatrics, University Hospital Carl Gustav Carus Dresden, TUD Dresden University of Technology (Author)
  • Elisabeth Unger - , Department of Paediatrics, University Hospital Carl Gustav Carus Dresden, TUD Dresden University of Technology (Author)
  • Normi Brück - , Department of Paediatrics (Author)
  • Reinhard Berner - , Department of Paediatrics, Department of Paediatrics, University Hospital Carl Gustav Carus Dresden, TUD Dresden University of Technology (Author)
  • Ursula Range - , Institute for Medical Informatics and Biometry (Author)
  • Annette Holl-Wieden - , University Hospital of Würzburg (Author)
  • Henner Morbach - , University Hospital of Würzburg (Author)
  • Anna Leszczynska - , Department of Ophthalmology (Author)
  • Viktoria Bau - , Department of Ophthalmology (Author)
  • Christian M Hedrich - , University of Liverpool (UOL) (Author)

Abstract

Non-infectious uveitis is associated with visual impairment and blindness. Non-biologic treatment for non-infectious uveitis is not based on strong evidence. A retrospective chart review was conducted to investigate treatment response to high-dose intravenous methylprednisolone (IVMP) in children with non-infectious uveitis. Fifty-six patients (93 eyes affected) were included. In 29% uveitis was associated with juvenile idiopathic arthritis. Uveitis predominately affected the anterior segment, was bilateral and recurrent. Complications were common and included visual loss, synechiae, cataract and/or retinal lesions. Patients received up to 5 IVMP at monthly intervals. Visual acuity improved at 3 and 6 months. Anterior chamber cells, synechiae, keratic precipitates, papillary and/or macular edema improved at 3 months. Children treated with ≥3 IVMP (vs 1 IVMP) experienced trends towards fewer relapses, fewer cataracts and less frequently required treatment with biologic agents. High-dose IVMP induce rapid improvement in children with non-infectious uveitis. Prospective randomized trials are required to confirm results.

Details

Original languageEnglish
Pages (from-to)108327
JournalClinical Immunology
Volume211
Publication statusPublished - Feb 2020
Peer-reviewedYes

External IDs

Scopus 85076838282

Keywords

Keywords

  • Administration, Intravenous, Adolescent, Adrenal Cortex Hormones/therapeutic use, Anti-Inflammatory Agents/therapeutic use, Arthritis, Juvenile/drug therapy, Child, Child, Preschool, Female, Humans, Male, Methylprednisolone/therapeutic use, Retrospective Studies, Treatment Outcome, Uveitis/drug therapy